SQZ-AACs (Oncology) is under clinical development by SQZ Biotechnologies and currently in Phase II for Head And Neck Cancer. According to GlobalData, Phase II drugs for Head And Neck Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SQZ-AACs (Oncology)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SQZ-AACs (Oncology) overview
Cell therapy is under development for the treatment of HPV16+ solid tumors like anal cancer, cervical cancer, head and neck cancer, penile cancer, rectal, vulval cancer and vaginal cancer. The therapy consists of engineered red blood cells which carry tumor-associated antigen. It is developed based on cell squeeze technology platform.
SQZ Biotechnologies overview
SQZ Biotechnologies (SQZ) is a pharmaceutical company. It develops cell-based therapies that harness the body’s natural immune system against cancer. The company utilizes CellSqueeze, a technology platform for engineering various cell functions as antigen presenting cells (APCs) for immune modulation to impact oncology and autoimmune disease applications. SQZ’s APC approach enables delivery of cancer-specific antigens to the cytosol of the APC which generates polyclonal T cell responses. The company collaborates with other academic institutions, pharmaceutical and biotechnology companies focusing on developing new cell therapies and approaches for that transform patient lives. It operates in Hong Kong and the US. SQZ is headquartered in Watertown, Massachusetts, the US.
For a complete picture of SQZ-AACs (Oncology)’s drug-specific PTSR and LoA scores, buy the report here.